Outlook Therapeutics, Inc.

OTLK Healthcare Biotechnology

Outlook Therapeutics, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $1.4 million.

Revenue
−99.4%
EPS
+72.7%
Free cash flow
−76.5%
Total debt
−47.1%

Quarter to June 2026, against a year earlier

0.43 0.01 −2.27%
Market cap
$106.9M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
n/a
Altman Z
−58.86
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 Sep '20 Sep '19 Sep '18 Sep '17 Sep '16
Total current assets
17.39 27.42 30.98 27.52 21.51 17.94 13.50 3.30 3.90 5.68
Total non-current assets
1.20 1.41 1.32 1.01 1.30 1.79 3.63 18.98 16.83 19.73
Total Assets
18.58 28.82 32.30 28.53 22.81 19.73 17.14 22.28 20.73 25.41
Total current liabilities
45.81 42.55 46.73 19.73 6.75 15.89 20.29 32.04 28.74 20.44
Total non-current liabilities
4.96 59.35 0.01 0.06 11.45 1.02 7.61 11.05 22.72 10.14
Total liabilities
50.77 101.90 46.74 19.79 18.20 16.91 27.91 43.09 51.46 30.58
Common Equity (Total)
(32.19) (73.08) (14.44) 8.74 4.61 2.83 (16.13) (25.54) (33.65) (5.17)
Shareholders Equity (Total)
(32.19) (73.08) (14.44) 8.74 4.61 2.83 (10.77) (20.81) (30.73) (5.17)
Total Debt
29.95 29.44 35.55 10.92 11.81 1.00 11.14 16.80 13.46 3.14

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 26 Oct 2026